Illinois is currently home to 2639 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes
NCT07005895
Recruiting
This remote study will evaluate the feasibility of using the Gatorade Sports Science Institute (GSSI) Labs App for remotely collecting hydration related outcomes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/27/2025
Locations: Advanced Personalized Ideation Center (API) and Gatorade Sports Science Institute (GSSI), PepsiCo Global R&D - Life Sciences, Chicago, Illinois
Conditions: Hydration
Register for Updates
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651
Recruiting
The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with Chronic Urticaria (CU), including both Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CINDU).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/27/2025
Locations: Endeavor Health, Glenview, Illinois
Conditions: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Register for Updates
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076
Recruiting
BH-30643-01 is a Phase 1/2, first-in-human, open label, dose escalation and expansion study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor (HER2) mutations. The study drug, BH-30643 capsules, will be self-administered by mouth twice daily in 21-day cycles. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago, Illinois
Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Register for Updates
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927
Recruiting
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: USOR - Illinois Cancer Specialists - Arlington Heights, Arlington Heights, Illinois
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Mobile Health Interventions to Prevent Heart Disease After Hypertensive Disorders of Pregnancy
NCT06523569
Recruiting
The purpose of this research is to study digital health interventions to prevent cardiovascular disease in individuals who have had a hypertensive disorder of pregnancy (HDP).
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
05/27/2025
Locations: Northwestern University, Dept. of Cardiology, Chicago, Illinois
Conditions: Hypertension in Pregnancy, Pre-Eclampsia, Eclampsia, Gestational Hypertension
Register for Updates
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259
Recruiting
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
05/27/2025
Locations: Local Institution - 0093, Chicago, Illinois
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
NCT06280950
Recruiting
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study fro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Northwestern University (Site #: 71110), Chicago, Illinois
Conditions: Liver Transplant
Register for Updates
Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis
NCT06264336
Recruiting
Nearly 1 million individuals in the United States have multiple sclerosis, which causes fatigue and problems with walking. Fatigue and walking problems are poorly treated, but exercise training, particularly high-intensity walking exercise, may help. This provide insight into whether high-intensity walking exercise can improve fatigue and walking problems in people with multiple sclerosis, which could improve quality of life and reduce economic burden.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/27/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis
Register for Updates
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/27/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Acute Myeloid Leukemias
Register for Updates
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
NCT06192758
Recruiting
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.
Gender:
MALE
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Prostate, Cancer
Register for Updates
Obsidio™ Conformable Embolic Registry
NCT06170619
Recruiting
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Hypervascular Tumors, Bleeding, Hemorrhage
Register for Updates
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
05/27/2025
Locations: Bluhm Cardiovascular Institute of Northwestern, Chicago, Illinois
Conditions: Heart Failure
Register for Updates